Welcome to our dedicated page for N2OFF SEC filings (Ticker: NITO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The N2OFF, Inc. (NASDAQ: NITO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, offering a structured view of how this clean tech and cleantech issuer reports its activities in renewable energy, agri-tech, and biotechnology. N2OFF files as a Nevada corporation under Commission File Number 001-40403, and its Forms 8-K, proxy statements, and related exhibits provide detailed information on material agreements, corporate actions, and subsidiary operations.
Recent Form 8-K filings describe N2OFF’s acquisition of MitoCareX Bio Ltd., a biotechnology company focused on drug discovery targeting cancer therapeutics via the mitochondrial SLC25 protein family, and the subsequent filing of an amended 8-K/A with supplemental business descriptions, risk factors, and pro forma financial information. Other 8-Ks outline the one-for-thirty-five reverse stock split of N2OFF’s common stock, Nasdaq notifications regarding minimum bid price compliance, and loan and partnership agreements supporting EU-based solar and battery storage projects developed with Solterra Renewable Energy Ltd.
Another key 8-K details a Securities Exchange Agreement with Voice Assist, Inc., under which N2OFF agreed to transfer all of its approximately 98% stake in Save Foods Ltd., an Israeli post-harvest treatment company, in exchange for equity and additional consideration structured through a services agreement. Additional filings report unregistered sales of equity securities, outcomes of annual and special stockholder meetings, and amendments to share incentive plans.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the core terms of each document, highlight significant business changes, and clarify how transactions affect N2OFF’s structure and focus areas. Users can quickly scan material event disclosures, equity issuance details, and governance matters to understand how N2OFF manages its RTB solar portfolio, MitoCareX biotech platform, and evolving relationship with Save Foods.
Nexentis Technologies, Inc. files its annual report outlining a major strategic shift into oncology drug discovery and renewable energy projects. The company completed the acquisition of MitoCareX Bio Ltd. in October 2025, making it a wholly owned subsidiary focused on mitochondrial-targeted therapies for cancers such as non-small cell lung and pancreatic cancer, using its proprietary MITOLINE™ computational platform.
Nexentis also expanded into European solar and battery storage through a February 2025 agreement to purchase 70% of SB Storage 1 S.R.L. alongside Solterra Renewable Energy. It exited its legacy post-harvest food business by transferring approximately 98% of Save Foods Ltd. to Voice Assist, Inc. in March 2026. As of June 30, 2025, non‑affiliate equity had a market value of $6,387,364, and as of March 31, 2026, 5,111,362 common shares were outstanding. The company, together with MitoCareX, operates with seven full-time and two part-time employees.
Nexentis Technologies Inc. large shareholder Lee Eun Young reported an open-market sale of 127 shares of common stock on January 29, 2026 at a weighted average price of $1.355 per share. After this small transaction, Lee Eun Young directly holds 479,524 shares of Nexentis common stock.
Nexentis Technologies Inc. reported the initial holdings of a major shareholder on a Form 3. Reporting person Lee Eun Young, identified as a ten percent owner, holds 479,651 shares of common stock directly. The filing records this ownership position and does not show any recent share purchases or sales.
Nexentis Technologies Inc. Schedule 13G: Eun Young Lee reports beneficial ownership of 479,524 shares of Common Stock, equal to 9.38% of the class based on 5,111,362 shares outstanding as of March 10, 2026. The filing shows sole voting and dispositive power over these shares and is signed by Eun Young Lee on March 23, 2026.
Nexentis Technologies Inc. has completed a strategic share exchange involving its majority-owned subsidiary Save Foods Ltd. and Voice Assist, Inc. On March 15, 2026, Nexentis transferred all of its Save Foods ordinary shares, representing approximately 98% of Save Foods’ issued and outstanding share capital, to Voice Assist.
In return, Nexentis received shares of Voice Assist common stock representing 19.99% of Voice Assist on a fully diluted basis, calculated immediately after closing. Nexentis also maintains a previously signed Services Agreement under which it provides advisory and related services to Voice Assist in exchange for deferred cash from future financings capped at $1,000,000, royalty consideration on defined “New Future Projects,” and a share of any “Ecolab Gross Proceeds.” The Services Agreement runs through calendar year 2026 with extension rights until all consideration is fully received.
Nexentis Technologies Inc. has called a special stockholder meeting on April 30, 2026 to approve several major capital structure changes. Stockholders will vote on a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑500, with the board choosing the exact ratio and timing if it proceeds.
They will also consider authorizing one or more non‑public offerings of up to 20,000,000 shares of common stock (or equivalents) for up to $100 million, at discounts of up to 20% below market, under Nasdaq Rule 5635(d). As of March 10, 2026, 5,111,362 shares of common stock were outstanding.
Another proposal seeks approval, under Nasdaq rules, for potential share issuances upon exercise of warrants tied to an amended credit facility with L.I.A. Pure Capital Ltd. that increases available financing from EUR 6,000,000 to EUR 10,000,000 and adds a price‑maintenance anti‑dilution feature. Stockholders will also vote on allowing adjournment of the meeting to solicit additional proxies if needed.
Nexentis Technologies Inc. is asking stockholders at a Special Meeting on April 30, 2026 to approve four proposals: a reverse stock split (board authority to set a ratio between 1‑for‑2 and 1‑for‑500), stockholder approval to issue up to 20,000,000 shares (aggregate) in one or more non‑public offerings with aggregate consideration up to $100,000,000 and a maximum discount of 20%, and approval of an Amended and Restated Facility Agreement that increases available credit from €6,000,000 to €10,000,000 and adds a warrant price‑maintenance anti‑dilution mechanism which may reduce warrant exercise price or increase warrant shares. The Board unanimously recommends FOR all proposals; the record date is March 10, 2026.
Nexentis Technologies Inc. reported that on February 20, 2026, it issued 600,000 shares of common stock to consultants as payment for investor relations and business development services. The company treated this as a private, unregistered equity issuance relying on the Section 4(a)(2) exemption from the Securities Act.
N2OFF, Inc. is changing its corporate name to Nexentis Technologies Inc. and its Nasdaq trading symbol from NITO to NXTS, effective on the Nasdaq Capital Market on February 26, 2026. The change was approved by the board and implemented through a Nevada charter amendment that did not require shareholder approval.
The company states that the name and brand now reflect its evolution into an AI and data-driven computational biotech platform centered on mitochondrial biology, precision oncology and inflammatory metabolic diseases, built around its wholly owned subsidiary MitoCareX Bio Ltd. It will continue to manage its European RTB solar projects and majority stake in Save Foods Ltd. as part of a broader portfolio. The filing notes that existing stockholder rights and the common stock CUSIP number remain unchanged and that no stockholder action is required.
N2OFF, Inc. Amendment No. 1: Ciro Leonardo Pierri reports beneficial ownership of 227,064 common shares, representing 4.44% of the class based on 5,111,362 shares outstanding as of February 23, 2026. The filing states these shares are held directly by the reporting person.